video
Video: Multiplex IHC and digital analysis for immuno-oncology
High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.
List view / Grid view
Assays
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
article
High-content imaging: challenges of the 3D world
The potential of three-dimensional cell culture models is now well-recognised by scientists; however, there are still some challenges. Margaritha Mysior and Jeremy Simpson address some of the common challenges of working with spheroids and organoid models – including how they are developed and how to obtain high-resolution, high-content images and…
article
Image-based characterisation of cancer biotherapeutics
Scientists from LifeArc, an independent medical research charity in the UK, explain how they’re using the latest imaging technologies to progress drug discovery campaigns and identify the most promising candidates for antibody-based therapies.
article
Compound and fragment screening by native mass spectrometry
Native mass spectrometry has the potential to be a fast, simple, highly sensitive and automatable technique for compound screening in drug design and discovery. In this article, Rod Chalk and Nicola Burgess-Brown discuss the key attributes of native mass spectrometry and reasons why it is not yet widely employed.
news
First in vitro lung cancer test launched
A new in vitro lung cancer diagnostic test has been launched by Roche Diagnostics to provide improved detection of cancer.
whitepaper
Application note: Detection of anti-drug antibody (ADA) using single molecule counting (SMCTM) technology
All biological therapeutics have the potential to induce an immunemediated response ranging from benign to severe adverse effects.
whitepaper
Whitepaper: Cubis® II pharma compliant by design
Sartorius Cubis® II is designed to follow US FDA data integrity principles that require data to be accurate, legible, contemporaneous, original and attributable.
article
Phenotypic profiling in drug discovery
Image-based phenotypic profiling of small molecules has been used for identification and characterisation of small molecules in drug discovery and can provide important insights into their mechanisms of action (MOA). This article discusses the use of phenotypic profiling in drug discovery and how machine-learning algorithms could help improve objectivity, processing…
webinar
A high-throughput approach to developing T-cell immunotherapies
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
news
‘Inconsistent’ use of antibodies found in laboratory experiments
16 May 2019 | By
Researchers say they have affirmed inconsistencies in the use of a common laboratory procedure called immunohistochemical staining.
article
AI-driven automated chemistry as a tool to accelerate drug discovery
Typically, early drug discovery campaigns start with the screening of chemical libraries to identify candidate chemotypes modulating a particular target and/or phenotype. Success of the primary screening depends on multiple factors related to both biology and chemistry. These include the target’s druggability, sensitivity and specificity of assay system, composition and…
whitepaper
Whitepaper: TruBIOME™ increases mouse model reproducibility
Ensure reproducibility with TruBIOME™ - the unique approach to generating research model colonies, which allows you complete control over their microbiome, from conception to cohort delivery.
article
Why do we have no effective treatments for osteoarthritis?
Osteoarthritis (OA) is a painful and debilitating disease of articular joints.1,2 Its clinical prevalence is as high as 21.6 percent of the population in the United States,3 which constitutes direct health costs of over 80 billion US dollars annually.4
article
The importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.
product
Fast molecular interaction screening for all your projects
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
